Tirzepatide
Tirzepatide is a prescription injectable medication used to treat type 2 diabetes, reduce excess body weight, and treat obstructive sleep apnea in adults, available as Mounjaro and Zepbound.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 8 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
Tirzepatide caused thyroid tumors in rats, including a type called medullary thyroid carcinoma (MTC). It is not yet known whether this same risk applies to people. Because of this, both Mounjaro and Zepbound must not be used by anyone who has — or has a family member who has — a history of MTC or a rare genetic condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your doctor right away if you notice a lump or mass in your neck, have trouble swallowing or breathing, or develop a persistent hoarse voice — these could be signs of a thyroid tumor. Routine blood or ultrasound screening for thyroid cancer is not reliably useful for catching this early in people taking tirzepatide.
📖 Tirzepatide: Patient Information Guide
A plain-language walkthrough of Tirzepatide — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Tirzepatide is the active ingredient in two brand-name products — Mounjaro and Zepbound — each approved for distinct uses.
- Mounjaro: Improves blood sugar control in adults and children aged 10 and older with type 2 diabetes, used alongside diet and exercise
- Mounjaro: Reduces the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes who are at high cardiovascular risk
- Zepbound: Reduces excess body weight and maintains weight loss long-term in adults with obesity, or adults who are overweight with at least one weight-related health condition — used with a reduced-calorie diet and increased physical activity
- Zepbound: Treats moderate to severe obstructive sleep apnea (OSA) in adults with obesity — used alongside diet and exercise
⚙️How it works▾
Tirzepatide binds to and activates two hormone receptors: the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor. Activating GLP-1 receptors boosts insulin release when blood sugar rises, reduces glucagon (a hormone that raises blood sugar), slows digestion, and curbs appetite. Adding GIP receptor activation appears to further support appetite and food-intake regulation. Both receptor types are also found in brain areas that control hunger, and animal studies show tirzepatide activates neurons in those regions — helping explain how it reduces body weight alongside blood sugar.
💊How it's taken▾
Tirzepatide is given as a once-weekly subcutaneous injection (under the skin) at any time of day, with or without food. Both Mounjaro and Zepbound are started at a low dose and gradually increased over several weeks — this step-up approach is designed to minimize stomach-related side effects. Your prescriber will determine your maintenance dose based on how well you respond and how you tolerate it.
- Inject in the abdomen, thigh, or (by another person) the back of the upper arm; rotate the site each week
- If you miss a dose, take it as soon as possible within 4 days (96 hours); if more than 4 days have passed, skip it and resume your normal schedule
- You can shift the day you take your weekly dose as long as at least 3 days (72 hours) separate two consecutive doses
🤒Side effects — in detail▾
The most common side effects with tirzepatide involve the stomach and digestive system, and they tend to be worst early on or after a dose increase.
- Nausea
- Diarrhea
- Decreased appetite
- Vomiting
- Constipation
- Indigestion (dyspepsia)
- Abdominal pain
- Burping, gas, or bloating
Serious reactions to watch for include severe abdominal pain (possible pancreatitis), signs of low blood sugar if you also use insulin or a sulfonylurea, sudden allergic reactions (swelling, trouble breathing), and symptoms of thyroid tumors (neck lump, hoarseness, difficulty swallowing). Seek medical help right away if any of these occur.
⚠️Warnings & precautions▾
- Thyroid tumor risk: Tirzepatide caused thyroid C-cell tumors in rats. Whether this applies to humans is unknown, but anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome must not use it. Watch for a neck lump, hoarseness, or trouble swallowing.
- Pancreatitis: Serious pancreas inflammation has been reported. Persistent or severe abdominal pain — sometimes radiating to the back — is a red flag. Stop the medication and call your doctor immediately.
- Low blood sugar (hypoglycemia): Risk increases when tirzepatide is combined with insulin or drugs like sulfonylureas. Your doctor may lower those doses when you start.
- Kidney injury: Severe vomiting or diarrhea can cause dehydration, which can harm the kidneys. Stay hydrated and let your doctor know if GI symptoms are severe.
- Gallbladder problems: Gallstones and gallbladder inflammation (cholecystitis) have been reported, particularly with weight loss.
- Serious allergic reactions: Anaphylaxis and angioedema (severe swelling) have been reported. Seek emergency care right away if this occurs.
- Aspiration risk during surgery: Because tirzepatide slows stomach emptying, there is a risk of inhaling stomach contents under general anesthesia. Tell your surgical team you are taking it.
- Diabetic retinopathy: Patients with a history of diabetic eye disease (retinopathy) should be monitored for progression during treatment.
🔀What it interacts with▾
Tirzepatide can interact with several medications, mainly because it slows how fast the stomach empties — which affects how quickly your body absorbs other drugs you take by mouth.
- Insulin and sulfonylureas (e.g., glipizide, glimepiride): Combining these with tirzepatide raises the risk of low blood sugar; your doctor may reduce their doses
- Oral hormonal contraceptives (birth control pills): Effectiveness may be reduced; switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase
- Warfarin and narrow-therapeutic-index drugs: Slower pill absorption can affect drug levels that need to stay in a precise range — monitoring is important
- Any oral medication: All pills taken by mouth have the potential for delayed absorption, so mention all your medications to your doctor or pharmacist
- Other tirzepatide products or GLP-1 receptor agonists: Do not combine — overlapping mechanisms increase the risk of side effects without added benefit
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- History of medullary thyroid carcinoma (MTC) or MEN 2: Tirzepatide is contraindicated — do not use it
- Serious allergy to tirzepatide: Do not use if you have ever had anaphylaxis or angioedema from it
- Pregnancy: Animal studies suggest a risk of fetal harm; discuss with your doctor whether the benefit outweighs the risk
- Breastfeeding: Tirzepatide appears in breast milk in very small amounts; the effects on a nursing infant are unknown — discuss with your doctor
- Oral contraceptives: Talk to your doctor before starting; you may need to switch to or add a non-oral method
- History of pancreatitis, gallbladder disease, or diabetic retinopathy: Tell your doctor — closer monitoring may be needed
- Severe gastroparesis (very slow stomach emptying): Zepbound is not recommended; discuss with your doctor
- Children under 10: Mounjaro has not been established as safe or effective in this age group; Zepbound has not been studied in children
- Older adults (65+): No overall differences in safety or effectiveness have been observed, but standard precautions apply
- Kidney or liver impairment: No dose adjustment is needed, but kidney function should be monitored if severe GI side effects cause dehydration
🚑If you take too much▾
If too much tirzepatide is taken, the most likely issues relate to its known side effects — particularly stomach symptoms and low blood sugar if combined with other glucose-lowering medications. Because tirzepatide stays in the body for approximately 5 days, any effects from an overdose could persist for some time. Contact the Poison Help line (1-800-222-1222) or seek medical attention right away if an overdose is suspected, and follow the guidance of healthcare providers for supportive care.
📡Pharmacodynamics — effects in the body▾
Tirzepatide lowers fasting and after-meal blood sugar by boosting insulin release and reducing glucagon — both in a way that depends on blood sugar levels, so the effect is naturally self-limiting. It also slows how quickly food leaves the stomach (gastric emptying), which smooths out blood sugar spikes after meals and reduces calorie absorption. Beyond blood sugar, it decreases food intake and reduces body weight, and increases the body's sensitivity to insulin.
🔬Pharmacokinetics — how your body processes it▾
After a subcutaneous injection, tirzepatide is absorbed gradually — blood levels typically peak somewhere between 8 and 72 hours after the dose. About 80% of the injected dose reaches the bloodstream. Tirzepatide is 99% bound to albumin (a protein in the blood), which helps slow its clearance and gives it a half-life of approximately 5 to 6 days — long enough to make once-weekly dosing effective. Steady, consistent drug levels in the blood are reached after about 4 weeks of weekly dosing. The drug is broken down through normal protein metabolism and eliminated through both urine and feces as metabolites; intact tirzepatide is not found in urine or feces. Neither kidney nor liver impairment meaningfully changes how the body handles tirzepatide.
📦How to store it▾
Do not freeze MOUNJARO. Store MOUNJARO in the original carton to protect from light. Store MOUNJARO single-dose pen and single-dose vial in a refrigerator at 2°C to 8°C (36°F to 46°F).
📄 Written from Tirzepatide’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Tirzepatide — the kind of thing our pharmacy team would talk through with you at the counter.
What's the difference between Mounjaro and Zepbound if they're the same drug? ▾
What side effects should I actually expect when I start? ▾
Should I worry about the thyroid cancer warning I read about? ▾
I'm also on birth control pills — is that a problem? ▾
What if I miss a dose? ▾
I'm scheduled for surgery — do I need to tell the anesthesia team I take this? ▾
Is Tirzepatide available over the counter? ▾
When was Tirzepatide first available? ▾
Who makes Tirzepatide? ▾
💬 Answers drafted from Tirzepatide’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Tirzepatide comes
Tirzepatide is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Mounjaro is used to improve blood sugar control in adults and children aged 10 and older with type 2 diabetes, as an addition to diet and exercise
- Mounjaro is used to reduce the risk of heart attack, stroke, or cardiovascular death in adults with type 2 diabetes at high cardiovascular risk
- Zepbound is used to reduce excess body weight and maintain that weight reduction long-term in adults with obesity or overweight with a related health condition, along with diet and exercise
- Zepbound is used to treat moderate to severe obstructive sleep apnea in adults with obesity, along with diet and exercise
- Both Mounjaro and Zepbound are injected subcutaneously (under the skin) once weekly, at any time of day, with or without food
- Inject in the abdomen, thigh, or — if another person is administering — the back of the upper arm; rotate injection sites with each dose
- Mounjaro and Zepbound KwikPen products are not recommended for self-administration by those who are visually impaired; Mounjaro KwikPen is also not recommended for self-administration by pediatric patients
- If using Mounjaro alongside insulin, give them as separate injections — never mixed together — though they may be given in the same body region
Show 12 more strengths Show fewer strengths
📊 Tirzepatide across the U.S. market
How Tirzepatide appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (82) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Tirzepatide is used
A general measure of how commonly Tirzepatide is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Tirzepatide is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Tirzepatide prescribed? Of the 1,596 medications we measure, Tirzepatide ranks #70 by Medicaid prescriptions — more than 96% of them.
Utilization by Tirzepatide product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
0.5 ML tirzepatide 10 MG/ML Auto-Injector Most dispensed
Summed across the 2 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2601743
0.5 ML tirzepatide 5 MG/ML Auto-Injector
Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2601761
0.5 ML tirzepatide 15 MG/ML Auto-Injector
Summed across the 2 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2601784
0.5 ML tirzepatide 20 MG/ML Auto-Injector
Summed across the 2 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2601767
0.5 ML tirzepatide 30 MG/ML Auto-Injector
Summed across the 2 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2601755
0.5 ML tirzepatide 25 MG/ML Auto-Injector
Summed across the 2 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2601773
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Tirzepatide, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 12 of 26 listed Tirzepatide NDCs with Medicaid activity.
🔍 Compare Tirzepatide products
A representative set of FDA-listed product records for Tirzepatide — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 2.5 mg/0.5 mL | Subcutaneous | A-S Medication Solutions | NDA | View NDC → |
| 5 mg/0.5 mL | Subcutaneous | A-S Medication Solutions | NDA | View NDC → |
| 7.5 mg/0.5 mL | Subcutaneous | A-S Medication Solutions | NDA | View NDC → |
| 10 mg/0.5 mL | Subcutaneous | A-S Medication Solutions | NDA | View NDC → |
| 12.5 mg/0.5 mL | Subcutaneous | A-S Medication Solutions | NDA | View NDC → |
| 15 mg/0.5 mL | Subcutaneous | A-S Medication Solutions | NDA | View NDC → |
| 2.5 mg/0.5 mL | — | BSP Pharmaceuticals SpA | DRUG FOR FURTHER PROCESSING | View NDC → |
| 5 mg/0.5 mL | — | BSP Pharmaceuticals SpA | DRUG FOR FURTHER PROCESSING | View NDC → |
| 7.5 mg/0.5 mL | — | BSP Pharmaceuticals SpA | DRUG FOR FURTHER PROCESSING | View NDC → |
| 10 mg/0.5 mL | — | BSP Pharmaceuticals SpA | DRUG FOR FURTHER PROCESSING | View NDC → |
| 12.5 mg/0.5 mL | — | BSP Pharmaceuticals SpA | DRUG FOR FURTHER PROCESSING | View NDC → |
| 15 mg/0.5 mL | — | BSP Pharmaceuticals SpA | DRUG FOR FURTHER PROCESSING | View NDC → |
| 2.5 mg/0.5 mL | Subcutaneous | Eli Lilly and Company × 12 listings | NDA | View NDC → |
| 4.17 mg/mL | Subcutaneous | Eli Lilly and Company × 8 listings | NDA | View NDC → |
| 5 mg/0.5 mL | Subcutaneous | Eli Lilly and Company × 12 listings | NDA | View NDC → |
| 7.5 mg/0.5 mL | Subcutaneous | Eli Lilly and Company × 12 listings | NDA | View NDC → |
| 8.33 mg/mL | Subcutaneous | Eli Lilly and Company × 8 listings | NDA | View NDC → |
| 10 mg/0.5 mL | Subcutaneous | Eli Lilly and Company × 12 listings | NDA | View NDC → |
| 12.5 mg/0.5 mL | Subcutaneous | Eli Lilly and Company × 12 listings | NDA | View NDC → |
| 12.5 mg/mL | Subcutaneous | Eli Lilly and Company × 8 listings | NDA | View NDC → |
| 15 mg/0.5 mL | Subcutaneous | Eli Lilly and Company × 12 listings | NDA | View NDC → |
| 16.7 mg/mL | Subcutaneous | Eli Lilly and Company × 8 listings | NDA | View NDC → |
| 20.8 mg/mL | Subcutaneous | Eli Lilly and Company × 8 listings | NDA | View NDC → |
| 25 mg/mL | Subcutaneous | Eli Lilly and Company × 8 listings | NDA | View NDC → |
| 2.5 mg/0.5 mL | — | Eli Lilly Italia SPA | DRUG FOR FURTHER PROCESSING | View NDC → |
| 2.5 mg/0.6 mL | — | Eli Lilly Italia SPA × 2 listings | DRUG FOR FURTHER PROCESSING | View NDC → |
| 5 mg/0.5 mL | — | Eli Lilly Italia SPA | DRUG FOR FURTHER PROCESSING | View NDC → |
| 5 mg/0.6 mL | — | Eli Lilly Italia SPA × 2 listings | DRUG FOR FURTHER PROCESSING | View NDC → |
| 7.5 mg/0.5 mL | — | Eli Lilly Italia SPA | DRUG FOR FURTHER PROCESSING | View NDC → |
| 7.5 mg/0.6 mL | — | Eli Lilly Italia SPA × 2 listings | DRUG FOR FURTHER PROCESSING | View NDC → |
| 10 mg/0.5 mL | — | Eli Lilly Italia SPA | DRUG FOR FURTHER PROCESSING | View NDC → |
| 10 mg/0.6 mL | — | Eli Lilly Italia SPA × 2 listings | DRUG FOR FURTHER PROCESSING | View NDC → |
| 12.5 mg/0.5 mL | — | Eli Lilly Italia SPA | DRUG FOR FURTHER PROCESSING | View NDC → |
| 12.5 mg/0.6 mL | — | Eli Lilly Italia SPA × 2 listings | DRUG FOR FURTHER PROCESSING | View NDC → |
| 15 mg/0.5 mL | — | Eli Lilly Italia SPA | DRUG FOR FURTHER PROCESSING | View NDC → |
| 15 mg/0.6 mL | — | Eli Lilly Italia SPA × 2 listings | DRUG FOR FURTHER PROCESSING | View NDC → |
| 2.5 mg/0.5 mL | — | Resilience US, LLC × 3 listings | DRUG FOR FURTHER PROCESSING | View NDC → |
| 5 mg/0.5 mL | — | Resilience US, LLC × 3 listings | DRUG FOR FURTHER PROCESSING | View NDC → |
| 7.5 mg/0.5 mL | — | Resilience US, LLC × 3 listings | DRUG FOR FURTHER PROCESSING | View NDC → |
| 10 mg/0.5 mL | — | Resilience US, LLC × 3 listings | DRUG FOR FURTHER PROCESSING | View NDC → |
| 12.5 mg/0.5 mL | — | Resilience US, LLC × 3 listings | DRUG FOR FURTHER PROCESSING | View NDC → |
| 15 mg/0.5 mL | — | Resilience US, LLC × 3 listings | DRUG FOR FURTHER PROCESSING | View NDC → |
| 💊Bulk drug substance | ||||
| 1 kg/kg | — | Apicore Pharmaceuticals Private Limited | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Assia Chemical Industries Ltd. - Teva Tech Site | BULK INGREDIENT | View NDC → |
| 25 mg/25 mg | — | Aurisco Pharmaceutical Co.,Ltd | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 g/g | — | Aurisco Pharmaceutical Co.,Ltd | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 5 g/5 g | — | Aurisco Pharmaceutical Co.,Ltd | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 10 g/10 g | — | Aurisco Pharmaceutical Co.,Ltd | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 20 g/20 g | — | Aurisco Pharmaceutical Co.,Ltd | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 50 g/50 g | — | Aurisco Pharmaceutical Co.,Ltd | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 100 g/100 g | — | Aurisco Pharmaceutical Co.,Ltd | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 200 g/200 g | — | Aurisco Pharmaceutical Co.,Ltd | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 500 g/500 g | — | Aurisco Pharmaceutical Co.,Ltd | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 kg/kg | — | Aurisco Pharmaceutical Co.,Ltd | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 kg/kg | — | Biocon Limited | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | BioVectra Inc. | BULK INGREDIENT | View NDC → |
| 1 mg/mg | — | Chatnaa Life Sciences LLC | BULK INGREDIENT | View NDC → |
| 100 g/100 g | — | Chengdu Shengnuo Biopharm Co., Ltd. | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 100 g/100 g | — | Chengdu Shengnuo Biopharm Co., Ltd. | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Chongqing Sintaho Pharmaceutical Co., Ltd. | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Corden Pharma Colorado, Inc. | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Darmerica, Llc | BULK INGREDIENT | View NDC → |
| 1 g/g | — | El-Peptido (Shanghai) Biopharmaceutical Co., Ltd | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 kg/kg | — | Eli Lilly and Company | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Fujian Genohope Biotech Ltd. | BULK INGREDIENT | View NDC → |
| 10 g/10 g | — | Guangdong Longfu Medicine Co., Ltd. | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Hangzhou Hotide Biotech Co.,Ltd | BULK INGREDIENT | View NDC → |
| 100 g/100 g | — | Hangzhou Younger International Co.,ltd | BULK INGREDIENT | View NDC → |
| 100 g/100 g | — | Harbin Jixianglong Biotech Co., Ltd. | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Hubei JXBio Pharmaceutical Co.,Ltd | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 g/g | — | Hybio Pharmaceutical Co., Ltd. × 3 listings | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Hybio Pharmaceutical Co. Ltd | BULK INGREDIENT | View NDC → |
Showing 200 of 250 products — FDA National Drug Code Directory. See every product, package size and price: browse all 250 Tirzepatide NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Tirzepatide — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Tirzepatide in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Tirzepatide went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 2601723 4 dose forms · 24 strengths
-
Dose form (SCDF) Auto-Injector RxCUI 2601731In current FDA listingsClinical drug / strength (SCD) 0.5 ML tirzepatide 10 MG/MLRxCUI 26017430.5 ML tirzepatide 15 MG/MLRxCUI 26017840.5 ML tirzepatide 20 MG/MLRxCUI 26017670.5 ML tirzepatide 25 MG/MLRxCUI 26017730.5 ML tirzepatide 30 MG/MLRxCUI 26017550.5 ML tirzepatide 5 MG/MLRxCUI 2601761 -
Dose form (SCDF) Injectable Solution RxCUI 2732436In current FDA listingsClinical drug / strength (SCD) 4.17 MG/MLRxCUI 27324528.33 MG/MLRxCUI 273245612.5 MG/MLRxCUI 273243716.7 MG/MLRxCUI 273244220.8 MG/MLRxCUI 273244625 MG/MLRxCUI 2732449 -
Dose form (SCDF) Injection RxCUI 2644395In current FDA listingsClinical drug / strength (SCD) 0.5 ML tirzepatide 10 MG/MLRxCUI 26444010.5 ML tirzepatide 15 MG/MLRxCUI 26443960.5 ML tirzepatide 20 MG/MLRxCUI 26444170.5 ML tirzepatide 25 MG/MLRxCUI 26444130.5 ML tirzepatide 30 MG/MLRxCUI 26444090.5 ML tirzepatide 5 MG/MLRxCUI 2644405 -
Dose form (SCDF) Pen Injector RxCUI 2734622In current FDA listingsClinical drug / strength (SCD) 2.4 ML tirzepatide 12.5 MG/MLRxCUI 27346232.4 ML tirzepatide 16.7 MG/MLRxCUI 27346282.4 ML tirzepatide 20.8 MG/MLRxCUI 27346322.4 ML tirzepatide 25 MG/MLRxCUI 27346362.4 ML tirzepatide 4.17 MG/MLRxCUI 27346402.4 ML tirzepatide 8.33 MG/MLRxCUI 2734644
Look up RxCUI 2601723 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Tirzepatide is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
…and 16 more on the FDA NDC directory.
RxNorm drug class
Tirzepatide belongs to the GLP-1 Receptor Agonist class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 8 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Eli Lilly and Company is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.